Glutamate as a neurotransmitter in the brain: review of physiology and pathology.
暂无分享,去创建一个
[1] R. Dingledine,et al. Peripheral glutamate receptors: molecular biology and role in taste sensation. , 2000, The Journal of nutrition.
[2] B. Meldrum,et al. Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4-phosphonophenylglycine. , 1999, European journal of pharmacology.
[3] N. Akaike,et al. Excitatory amino acid responses in relay neurons of the rat lateral geniculate nucleus , 1999, Neuroscience.
[4] M. Mishina,et al. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn , 1999, Nature.
[5] T. Soderling,et al. Calcium promotes cell survival through CaM-K kinase activation of the protein-kinase-B pathway , 1998, Nature.
[6] F. Nicoletti,et al. Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.
[7] D. Figlewicz,et al. Glutamate Potentiates the Toxicity of Mutant Cu/Zn-Superoxide Dismutase in Motor Neurons by Postsynaptic Calcium-Dependent Mechanisms , 1998, The Journal of Neuroscience.
[8] D. Attwell,et al. Stoichiometry of the Glial Glutamate Transporter GLT-1 Expressed Inducibly in a Chinese Hamster Ovary Cell Line Selected for Low Endogenous Na+-Dependent Glutamate Uptake , 1998, The Journal of Neuroscience.
[9] G. Coruzzi,et al. Glutamate-receptor genes in plants , 1998, Nature.
[10] K. P. Lehre,et al. The Number of Glutamate Transporter Subtype Molecules at Glutamatergic Synapses: Chemical and Stereological Quantification in Young Adult Rat Brain , 1998, The Journal of Neuroscience.
[11] E. Gouaux,et al. Structure of a glutamate-receptor ligand-binding core in complex with kainate , 1998, Nature.
[12] G. Collingridge,et al. The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus , 1998, Neuropharmacology.
[13] P. Ornstein,et al. Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia , 1998, Neuropharmacology.
[14] Masahiko Watanabe,et al. Functional Change of NMDA Receptors Related to Enhancement of Susceptibility to Neurotoxicity in the Developing Pontine Nucleus , 1998, The Journal of Neuroscience.
[15] M. Rogawski,et al. GluR5 kainate receptor mediated synaptic transmission in rat basolateral amygdala in vitro , 1998, Neuropharmacology.
[16] Y. Sagara,et al. The Activation of Metabotropic Glutamate Receptors Protects Nerve Cells from Oxidative Stress , 1998, The Journal of Neuroscience.
[17] B. Moghaddam,et al. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.
[18] F. Fonnum,et al. Synaptic Vesicular Localization and Exocytosis ofl-Aspartate in Excitatory Nerve Terminals: A Quantitative Immunogold Analysis in Rat Hippocampus , 1998, The Journal of Neuroscience.
[19] R. Faull,et al. 3‐Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration , 1998, Neuroreport.
[20] C. Fiorillo,et al. Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons , 1998, Nature.
[21] A. Rodríguez-Moreno,et al. Kainate Receptor Modulation of GABA Release Involves a Metabotropic Function , 1998, Neuron.
[22] F. Nicoletti,et al. Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells , 1998, Neuroscience.
[23] H. Betz,et al. Evidence for a Tetrameric Structure of Recombinant NMDA Receptors , 1998, The Journal of Neuroscience.
[24] J. Rothstein,et al. EAAC1, a high-affinity glutamate tranporter, is localized to astrocytes and gabaergic neurons besides pyramidal cells in the rat cerebral cortex. , 1998, Cerebral cortex.
[25] D. Schoepp,et al. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. , 1998, The Journal of pharmacology and experimental therapeutics.
[26] A. Yakovlev,et al. Neuroprotective effects of group III mGluR in traumatic neuronal injury. , 1997, Journal of neurotrauma.
[27] K Naujoks,et al. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. , 1997, Brain research. Molecular brain research.
[28] J. Coyle,et al. N-Acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo , 1997, Neuroscience Letters.
[29] D. Goff,et al. Glutamate in schizophrenia: clinical and research implications , 1997, Schizophrenia Research.
[30] S. Kwak,et al. AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA , 1997, Brain Research.
[31] P. Somogyi,et al. Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1α, mGluR2 and mGluR5, relative to neurotransmitter release sites , 1997, Journal of Chemical Neuroanatomy.
[32] H. Ohmori,et al. A Postsynaptic Excitatory Amino Acid Transporter with Chloride Conductance Functionally Regulated by Neuronal Activity in Cerebellar Purkinje Cells , 1997, The Journal of Neuroscience.
[33] J. Storm-Mathisen,et al. Differential Developmental Expression of the Two Rat Brain Glutamate Transporter Proteins GLAST and GLT , 1997, The European journal of neuroscience.
[34] F. Bordi,et al. The Glycine Antagonist GV150526 Protects Somatosensory Evoked Potentials and Reduces the Infarct Area in the MCAo Model of Focal Ischemia in the Rat , 1997, Experimental Neurology.
[35] Richard Granger,et al. Evidence That a Positive Modulator of AMPA-Type Glutamate Receptors Improves Delayed Recall in Aged Humans , 1997, Experimental Neurology.
[36] O. Steward,et al. Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[37] W. White,et al. Effects of the novel NMDA antagonists CP-98,113, CP-101,581 and CP-101,606 on cognitive function and regional cerebral edema following experimental brain injury in the rat. , 1997, Journal of neurotrauma.
[38] F. Nicoletti,et al. The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.
[39] J. Urenjak,et al. Altered glutamatergic transmission in neurological disorders: From high extracellular glutamate to excessive synaptic efficacy , 1997, Progress in Neurobiology.
[40] P N Leigh,et al. Excitotoxicity in ALS , 1996, Neurology.
[41] A. Faden,et al. Activation of Metabotropic Glutamate Receptor Subtype mGluR1 Contributes to Post-Traumatic Neuronal Injury , 1996, The Journal of Neuroscience.
[42] K. Flanders,et al. Transforming growth factors-β protect primary rat hippocampal neuronal cultures from degeneration induced by β-amyloid peptide , 1996, Brain Research.
[43] R Lujan,et al. Perisynaptic Location of Metabotropic Glutamate Receptors mGluR1 and mGluR5 on Dendrites and Dendritic Spines in the Rat Hippocampus , 1996, The European journal of neuroscience.
[44] P. Somogyi,et al. Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone , 1996, Nature.
[45] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.
[46] P. Leeson,et al. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. , 1996, The Journal of pharmacology and experimental therapeutics.
[47] J. Schulz,et al. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases , 1996, Neuroscience.
[48] L. Zuck,et al. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia , 1995, Neuroreport.
[49] J. Rothstein,et al. Neuroprotective Strategies in a Model of Chronic Glutamate‐Mediated Motor Neuron Toxicity , 1995, Journal of neurochemistry.
[50] A. Levey,et al. Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis , 1995, Annals of neurology.
[51] K. Wada,et al. Functional Comparison of d‐Serine and Glycine in Rodents: The Effect on Cloned NMDA Receptors and the Extracellular Concentration , 1995, Journal of neurochemistry.
[52] J. Grotta,et al. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. , 1995, Stroke.
[53] Richard F. Thompson,et al. Enhanced glutamatergic neurotransmission facilitates classical conditioning in the freely moving rat , 1995, Neuroscience Letters.
[54] R. Duvoisin,et al. The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.
[55] T Kuner,et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. , 1994, Science.
[56] R. Balázs,et al. Selective stimulation of excitatory amino acid receptor subtypes and the survival of granule cells in culture: effect of quisqualate and AMPA , 1994, Neurochemistry International.
[57] William A. Horne,et al. The naming of voltage-gated calcium channels , 1994, Neuron.
[58] P. Conn,et al. L-cysteine sulfinic acid as an endogenous agonist of a novel metabotropic receptor coupled to stimulation of phospholipase D activity. , 1994, Molecular pharmacology.
[59] A. N. van den Pol,et al. Ionotropic glutamate‐receptor gene expression in hypothalamus: Localization of AMPA, kainate, and NMDA receptor RNA with in situ hybridization , 1994, The Journal of comparative neurology.
[60] P. Nunn,et al. Neuronal damage induced by ß-N-oxalylamino-l-alanine, in the rat hippocampus, can be prevented by a non-NMDA antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline , 1993, Brain Research.
[61] Josemir W Sander,et al. The excitatory amino acid antagonist d-CPP-ene (SDZ EAA-494) in patients with epilepsy , 1993, Epilepsy Research.
[62] L. Jarrard,et al. Selective excitotoxic pathology in the rat hippocampus , 1993, Neuropathology and applied neurobiology.
[63] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[64] P. Suzdak,et al. Serine-O-phosphate has affinity for type IV, but not type I, metabotropic glutamate receptor. , 1993, Neuroreport.
[65] B. Meldrum. Amino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disorders , 1993, Brain Research Reviews.
[66] J. Bénavidès,et al. Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18h) therapeutic window , 1993, Brain Research.
[67] T. Gordh,et al. The NMDA-receptor antagonist CPP abolishes neurogenic ‘wind-up pain’ after intrathecal administration in humans , 1992, Pain.
[68] P. Ascher,et al. Equilibrium and kinetic study of glycine action on the N‐methyl‐D‐aspartate receptor in cultured mouse brain neurons. , 1992, The Journal of physiology.
[69] Bert Sakmann,et al. Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes , 1992, Science.
[70] J. Mcdonald,et al. The metabotropic excitatory amino acid receptor agonist 1S,3R-ACPD selectively potentiates N-methyl-D-aspartate-induced brain injury. , 1992, European journal of pharmacology.
[71] D. Schoepp,et al. Activation of hippocampal metabotropic excitatory amino acid receptors leads to seizures and neuronal damage , 1992, Neuroscience Letters.
[72] M. Beal,et al. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.
[73] B. Meldrum,et al. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice , 1991, Epilepsy Research.
[74] B. Sakmann,et al. A family of AMPA-selective glutamate receptors. , 1990, Science.
[75] E. Mackenzie,et al. The pharmacotherapy of focal cortical ischaemia in the mouse , 1990, Brain Research.
[76] R. Zatorre,et al. Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. , 1990, The New England journal of medicine.
[77] S. Heinemann,et al. Cloning by functional expression of a member of the glutamate receptor family , 1989, Nature.
[78] D. Choi,et al. Beta-N-methylamino-L-alanine neurotoxicity: requirement for bicarbonate as a cofactor. , 1988, Science.
[79] P. Nunn,et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. , 1987, Science.
[80] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[81] R. Schwarcz,et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.
[82] T. Pedley,et al. Regional cerebral blood flow in the rat during prolonged seizure activity , 1980, Brain Research.
[83] O. Ottersen,et al. The role of epileptic activity in hippocampal and ‘remote’ cerebral lesions induced by kainic acid , 1980, Brain Research.
[84] J. Olney,et al. GLUTAMATE‐INDUCED BRAIN DAMAGE IN INFANT PRIMATES , 1972, Journal of neuropathology and experimental neurology.
[85] J. Olney. GLUTAMATE‐INDUCED NEURONAL NECROSIS IN THE INFANT MOUSE HYPOTHALAMUS: An Electron Microscopic Study , 1971, Journal of neuropathology and experimental neurology.
[86] D. R. Curtis,et al. THE EXCITATION AND DEPRESSION OF SPINAL NEURONES BY STRUCTURALLY RELATED AMINO ACIDS , 1960, Journal of neurochemistry.
[87] T. Hayashi,et al. A physiological study of epileptic seizures following cortical stimulation in animals and its application to human clinics. , 1952, The Japanese journal of physiology.
[88] J. Olney,et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. , 1999, Science.
[89] S. Amara,et al. Excitatory amino acid transporters: a family in flux. , 1999, Annual review of pharmacology and toxicology.
[90] M. Riepe,et al. Amyotrophic lateral sclerosis and glutamate. , 1998, Restorative neurology and neuroscience.
[91] J. Kristensen. Intrathecal Administration of a Competitive NMDA Receptor Antagonist for Pain Treatment , 1997 .
[92] E. Gamzu,et al. Clinical Experience with the NMDA Ion Channel Blocker, Aptiganel Hydrochloride (CERESTAT®) , 1997 .
[93] J. Pin,et al. Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.
[94] M. Schmutz,et al. 1 – Selfotel (CGS19755) , 1997 .
[95] I. Kilpatrick,et al. The neurotransmitter candidature of sulphur-containing excitatory amino acids in the mammalian central nervous system. , 1996, Pharmacology & therapeutics.
[96] S. Heinemann,et al. Cloned glutamate receptors. , 1994, Annual review of neuroscience.
[97] R. Gill. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. , 1994, Cerebrovascular and brain metabolism reviews.
[98] P. Conn,et al. Metabotropic glutamate receptors in brain function and pathology. , 1993, Trends in pharmacological sciences.
[99] B. Meldrum. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. , 1990, Cerebrovascular and brain metabolism reviews.